Marken announced a new collaboration with RareChannels, a global web-based reference which allows manufactures of rare disease therapies and their affiliates to find customized logistic solutions.

According to the National Institutes of Health (NIH), 7,000 different rare diseases, sometimes referred to as ‘orphan’ diseases, affect more than 300 million people worldwide.  Important scientific research has led to the development of new diagnostic and therapeutic procedures to treat these diseases.  

Marken has the capability to deliver any drug product, vaccine or medical device to patients anywhere in the world, regardless of complexity. Nearly half of all orphan drugs are biologically-derived and must be handled carefully with appropriate temperature controls and GPS tracking in order to assure quality of delivery. 

Wes Wheeler, Marken’s chief executive officer, said, “We are proud to offer our services to the pharmaceutical companies dedicated to finding solutions and treatments for rare diseases.  Marken’s extensive network is well-positioned to provide time and temperature sensitive services, with end-to-end visibility, to the pharmaceutical industry. We look forward to working with RareChannels on the important challenges they face in the future.”

Carol Dickerson, founder & chief executive officer of RareChannels, said, “When managing the nuances within specialty distribution and market access for a rare manufacturer, I was often frustrated with the accessibility to real-world experienced, content-expert specialists for the customized solutions we needed.  Our issues were not those of large mainstream pharma, and the size of my organization’s needs, and budget, also did not suit the cookie-cutter solution-models that existed.  I then created this concept solely to bring cures to the globe faster, cheaper, better, by building a multilingual, web-based, category or term-searchable resource to directly find niche-experts in rare. Marken’s undeniable global presence, and intense focus on specializing their many deliverables for these new therapies, makes them a perfect Partner in Rare.  RareChannels is very proud and excited to have them on board.”